Fintel reports that on August 8, 2023, HC Wainwright & Co. reiterated coverage of GT Biopharma (NASDAQ:GTBP) with a Buy recommendation. Analyst Price Forecast Suggests 1,140.44% Upside As of August 2, 2023, the average one-year price target for GT Biopharma is 3.57. The forecasts range from a low of 2.02…
bubmagAugust 9, 2023